东南亚中重度二尖瓣狭窄患者抗凝强度与结局
本研究为多中心回顾性研究,纳入泰国两家医院2013至2018年933例未行瓣膜置换或修复的风湿性二尖瓣狭窄患者,随访3538患者年。结果显示标准INR 2.0-3.0与高强度INR 2.5-3.5的净不良临床事件率相当,但标准强度血栓栓塞发生率更高、大出血更低。
要点
- 标准INR 2.0-3.0与高强度INR 2.5-3.5净不良临床事件率无显著差异。
- 标准INR血栓栓塞风险更高,大出血风险更低。
- 两种INR强度颅内出血率无显著差异。
核心结论
- 标准抗凝强度(INR 2.0-3.0)是亚洲中重度风湿性二尖瓣狭窄患者的适宜范围。
- 高强度抗凝(INR 2.50-3.50)进一步减少血栓栓塞但增加大出血,不增加颅内出血。
研究设计与样本
- 多中心回顾性研究,纳入泰国两家医院2013至2018年933例未行瓣膜置换或修复、需长期华法林治疗的风湿性二尖瓣狭窄患者。
主要发现
- 随访期间发生149例血栓栓塞事件(4.2/100患者年)和132例大出血事件(3.7/100患者年)。
- 净不良临床事件在INR 2.50-2.99最低,INR 2.00-2.49与3.00-3.50之间无显著差异。
- 标准INR(2.0-3.0)与高强度INR(2.5-3.5)净不良临床事件率相当(IRR 0.99,95%CI 0.66-1.54,P=0.99)。
- 两种INR强度颅内出血率无显著差异。
关键数值与推荐
- 标准INR范围2.0-3.0,高强度INR范围2.5-3.5。
- 净不良临床事件最低INR区间为2.50-2.99。
临床怎么用
- 对于亚洲中重度风湿性二尖瓣狭窄需长期华法林抗凝患者,可考虑标准INR 2.0-3.0作为适宜抗凝强度。
- 若选择高强度INR 2.5-3.5,需权衡血栓栓塞减少与大出血增加的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the optimal anticoagulation intensity of warfarin in a South-East Asian population with moderate-to-severe rheumatic mitral stenosis. METHODS: A multicentre, retrospective study examined patients with rheumatic mitral stenosis who had not undergone valve replacement or repair and required long-term warfarin therapy at two hospitals in Thailand from 2013 to 2018. The main outcomes were thromboembolism and major bleeding. Incidence rate ratios for these events at each level of anticoagulation intensity (international normalized ratio [INR]) were compared. RESULTS: The study included 933 patients with 3538 patient-years of follow-up, a mean follow-up of 3.8 years and 23 700 INR values. Mean age was 56.1 ± 11.8 years. During follow-up, there were 149 thromboembolic events (4.2 per 100 patient-years) and 132 major bleeding events (3.7 per 100 patient-years). Net adverse clinical events were lowest at INR 2.50-2.99, with no significant difference between INR 2.00-2.49 and 3.00-3.50. Standard INR (2.0-3.0) and high-intensity INR (2.5-3.5) had comparable net adverse clinical event rates (incidence rate ratio 0.99, 95% confidence interval [CI] 0.66-1.54, P = .99). However, thromboembolism incidence was higher with standard INR (incidence rate ratio 2.49, 95% CI 1.13-6.23, P = .013), while major bleeding was lower (incidence rate ratio 0.57, 95% CI 0.35-0.98, P = .045). No significant difference in intracranial haemorrhage rates was observed between the two INR intensities. CONCLUSION: The standard anticoagulation intensity is an optimal range for Asian population with moderate-to-severe rheumatic mitral stenosis. High intensity anticoagulation (INR of 2.50-3.50) further reduces thromboembolism but increases major bleeding but not intracranial haemorrhage.
引用
- Puchsaka P, Rattanavipanon W, Phetroong S, et al. Anticoagulation intensity and outcomes among southeast-Asians with moderate-to-severe mitral valve stenosis. Br J Clin Pharmacol. 2025. PMID: 40065497. doi:10.1002/bcp.70034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。